FDA Drug Safety Information for June 25, 2024

Jun 252024
 

Date Brand Name(s) Description Type Reason Company  6/25/2024 Glenmark Potassium Chloride Extended Release 750mg Capsules, 100 count and 500 count Drugs Failed dissolution Glenmark Pharmaceuticals,

FDA Drug Safety Information for June 12, 2024

Jun 122024
 

Date Brand Name(s) Description Type Reason Company  6/12/2024 Suntegrity Sunscreen foundation Drugs Higher than acceptable microbiological mold count Suntegrity Skincare

FDA Drug Safety Information June 11, 2024

Jun 112024
 

Date Brand Name(s) Description Type Reason Company  6/11/2024 Ram It, To The Moon Dietary Supplements for Male Sexual Enhancement Dietary Supplements, Drugs Product is tainted

FDA Drug Safety Information for June 5, 2024

Jun 052024
 

Date Brand Name(s) Description Type Reason Company  6/5/2024 StellaLife Inc. Homeopathic StellaLife Oral Care Products Drugs Microbial contamination HomeoCare Laboratories Inc.

FDA Novel Drug Approvals – May 2024

Jun 032024
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Imdelltra tarlatamab-dlle 5/16/2024 To treat extensive stage small cell

FDA Drug Safety Information for May 31, 2024

May 312024
 

Date Brand Name(s) Description Type Reason Company  5/31/2024 Medline SubG Endotracheal Tubes with Subglottic Suction and kits that contain these devices Medical Devices The inflation

FDA Drug Safety Information for May 10, 2024

May 102024
 

Date Brand Name(s) Description Type Reason Company  5/10/2024 Ethicon Megadyne Mega Soft Pediatric Patient Return Electrode Medical Devices Reports of patient burn injuries Megadyne Medical

FDA Novel Drug Approvals – April 2023

May 012024
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Qalsody tofersen 4/25/2023 To treat amyotrophic lateral sclerosis in

FDA Novel Drug Approvals – April 2024

May 012024
 

Drug Name Active Ingredient(s) Approval Date FDA-Approved Use on Approval Date Press Release Drug Trials Snapshot Xolremdi mavorixafor 4/26/2024 To treat WHIM syndrome (warts, hypogammaglobulinemia,

FDA Drug Safety Information for April 23, 2024

Apr 232024
 

Date Brand Name(s) Description Type Reason Company  4/23/2024 Schwinnng Herbal Dietary Supplement Drugs Product is tainted with Nortadalafil STOP CLOPEZ CORP 4/23/2024 Dr. Reddy’s Sapropterin

 Older Entries  Newer Entries